{"entity":{"id":"nct06764485","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer","aka":[],"tldr":"A phase 3 trial testing BMS-986365 in prostate cancer, active and no longer recruiting.","summary":"A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer is a phase 3 interventional study registered as NCT06764485, led by Celgene, and active but no longer recruiting on the registry. Official title: A Phase 3, Two-part, Randomised, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge. Planned enrolment is 960 participants (estimated). The study started in 2025-03-13 and primary completion is expected in 2027-09-12. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06764485","url":"https://clinicaltrials.gov/study/NCT06764485"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["bms-986365"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06764485","phase":"3","setting":"A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge","sponsor":"Celgene","participation":[{"nct":"NCT06764485","source":"https://clinicaltrials.gov/study/NCT06764485","fetchedAt":"2026-10-07T16:55:00.061Z","studySha256":"92cc621f43daf3532864d0f109070dc64f5d6c1c67792e43660851895aaba2ed","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-30","leadSponsor":"Celgene","collaboratorCount":0,"minimumAge":"18 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":960,"enrolmentType":"ESTIMATED","siteCount":227,"recruitingSiteCount":0,"countries":["Argentina","Australia","Austria","Brazil","Canada","Chile","China","Czechia","Denmark","Finland","France","Germany","Ireland","Israel","Italy","Mexico","Poland","Puerto Rico","Romania","Slovakia","South Korea","Spain","Sweden","Taiwan","United Kingdom","United States"]}],"started":"2025-03-13","startedType":"actual","enrolled":960,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06764485/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"bms-986365","kind":"drug","name":"BMS-986365","route":"/drugs/bms-986365/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}